Medical Affairs 360 Announces Regimmune Poster Presentations at the 2026 Tandem Meeting

San Diego, CA. December 23, 2025 – Medical Affairs 360 LLC, a medical advisory firm offering services to pharmaceutical and biotechnology companies, is pleased to announce the acceptance of two Posters to be presented at the 2026 Tandem Meeting (Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR) by Regimmune, Inc., a client partner, next February 4-7, 2026, at the Salt Palace Convention Center in Salt Lake City, Utah. The Posters will be presented in person during the “Meet the Poster Authors” session on February 5, 2026, 630 PM – 800 PM MST in Hall AB.

The first Poster will be presented by Phil Yeung, Pharm. D., Comparative Evaluation of Baseline Risk Factors and Acute GVHD Outcomes in Allogeneic Hematopoietic Cell Transplant (allo-HCT): RGI-2001 or Abatacept-Based Prophylaxis Studies explores the outcomes of FDA-approved Abatacept vs. RGI-2001, a novel invariant natural killer T (iNKT) cell agonist for aGVHD prophylaxis.

Cross-trial comparison requires special data handling to enable effective and cogent comparisons. This research applied a unifying statistical framework to enable comparisons for 2 different studies from published data.

“This poster illustrates how differences in patient populations, study design, and statistical methodology can influence the interpretation of aGVHD prevention strategies,” said Phil Yeung, Pharm.D., lead author and Director of Clinical Evidence & Analytics at Medical Affairs 360 LLC.

The second Poster will be presented by Zachariah DeFilipp, MD, Associate Professor of Medicine at Massachusetts General Hospital and Director of BMT Clinical Research at Harvard Medical School. The poster, Delayed Onset of Chronic GVHD in Patients Receiving RGI-2001Prophylaxis: A Multicenter Phase 2b Study with Comparison to CIBMTR Matched Cohort Data further explores delayed onset data of chronic GVHD from the Phase 2 study for RGI-2001 published in the October 23, 2025 issue of Blood.

Medical Affairs 360 provided strategic medical and scientific support throughout the program’s development, from clinical protocol design and safety oversight to Key Opinion Leader (KOL) advisory and publication strategy, ensuring scientific rigor and alignment with global standards of excellence. “These abstracts and poster presentations demonstrates the value of sustained collaboration between biotechnology innovators and specialized medical advisory partners working together to advance transformative therapies to patients in need, ” said Kenneth Tong, President and Founder of Medical Affairs 360 LLC.

About RGI-2001
RGI-2001, is a liposomal formulation of an alpha-galactosylceramide (alpha-GalCer) analog. alpha-GalCer is a ligand for CD1d expressed on antigen presenting cells and invariant NKT cells. It was discovered that a liposomal alpha-GalCer promotes tolerogenic immune cascade, resulting in the activation and expansion of Tregs.  RGI-2001 has been evaluated for prevention of Graft-versus-Host Disease (GvHD) in patients undergoing HLA-matched allogeneic hematopoietic stem cell transplantation (HSCT) for the treatment of hematological malignancies. A Phase 2b study (NCT04014790) has completed the enrollment of 49 patients: RGI-2001 was well tolerated and demonstrated preliminary signs of efficacy